Insuline icodec injectable à administration hebdomadaire pour les adultes vivant avec le diabète

[Article in French]

Affiliations

¹ Département de médecine, St. Michael's Hospital, University of Toronto, Toronto, Ont.
² Département de médecine, St. Michael's Hospital, University of Toronto, Toronto, Ont. catherine.yu@unityhealth.to.

[Article in French]

Sooyoun Shin et al. CMAJ. 2025.

. 2025 Mar 24;197(11):E303-E304.

doi: 10.1503/cmaj.241037-f.

¹ Département de médecine, St. Michael's Hospital, University of Toronto, Toronto, Ont.
² Département de médecine, St. Michael's Hospital, University of Toronto, Toronto, Ont. catherine.yu@unityhealth.to.

No abstract available

Conflict of interest statement

Intérêts concurrents :: Aucun déclaré.

1. AWIQLI insulin icodec injection [monographie du produit]. Mississauga (ON): Novo Nordisk Canada Inc; 2024. Accessible ici : https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/awiqli-en-p... (consulté le 22 juin 2024).
1. Bajaj HS, Ásbjörnsdóttir B, Bari TJ, et al. . Once-weekly insulin icodec compared with daily basal insulin analogues in type 2 diabetes: participant-level meta-analysis of the ONWARDS 1–5 trials. Diabetes Obes Metab 2024;26:3810–20. - PubMed
1. Lingvay I, Asong M, Desouza C, et al. . Once-weekly insulin icodec vs once-daily insulin degludec in adults with insulin-naive type 2 diabetes. JAMA 2023;330:228–37. - PMC - PubMed
1. Rosenstock J, Bain SC, Gowda A, et al. . Weekly icodec versus daily glargine U100 in type 2 diabetes without previous insulin. N Engl J Med 2023;389:297–308. - PubMed
1. Russell-Jones D, Babazono T, Cailleteau R, et al. . Once-weekly insulin icodec versus once-daily insulin degludec as part of a basal-bolus regimen in individuals with type 1 diabetes (ONWARDS 6): a phase 3a, randomised, open-label, treat-to-target trial. Lancet 2023;402:1636–47. - PubMed